Goldman Sachs’s 10x Genomics TXG Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$2.91M Buy
+137,300
New +$2.74M ﹤0.01% 4191
2023
Q1
Sell
-939,000
Closed -$34.2M 6237
2022
Q4
$34.2M Buy
+939,000
New +$30.7M 0.01% 1479
2021
Q2
Sell
-10,000
Closed -$1.81M 6527
2021
Q1
$1.81M Buy
+10,000
New +$1.73M ﹤0.01% 4092

Other funds holding TXG

Goldman Sachs's TXG Position: Q1 2026 in Review

Goldman Sachs increased its 10x Genomics (TXG) stake by 29% in Q1 2026, buying an estimated $17.7M and bringing the position to 3,971,800 shares worth $84.3M. The position accounts for 0.01% of the portfolio, ranked #1161.

Goldman Sachs first reported a position in TXG in Q3 2019 and has held it in 27 quarters since. The position peaked at $105M in Q2 2021. 329 funds tracked by Wall St. Rank hold TXG as of Q1 2026.

  • Goldman Sachs held 3,971,800 shares of 10x Genomics worth $84.3M as of Q1 2026.
  • Goldman Sachs bought 884,533 10x Genomics shares in Q1 2026, an estimated $17.7M.
  • 10x Genomics made up 0.01% of Goldman Sachs's portfolio in Q1 2026, its #1161 holding.
  • Goldman Sachs first reported a position in 10x Genomics in Q3 2019 and has held it in 27 quarters since.
  • Goldman Sachs's 10x Genomics position peaked at $105M in Q2 2021.
  • 329 funds tracked by Wall St. Rank held 10x Genomics as of Q1 2026.

Based on Goldman Sachs's 13F filing for Q1 2026, filed 15 May 2026.